Get App
Moneycontrol

Co-Partners

Associate Partners

Last Updated : Mar 28, 2019 03:23 PM IST | Source: Moneycontrol.com

Buy Laurus Labs; target of Rs 535: HDFC Securities

HDFC Securities is bullish on Laurus Labs has recommended buy rating on the stock with a target price of Rs 535 in its research report dated March 28, 2019.

Broker Research @moneycontrolcom
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

HDFC Securities' research report on Laurus Labs


Laurus has received Global Fund orders for the HIV drug, TLD, following a tentative approval from the US FDA last month. This is a big positive for the company and reinstates investor confidence in the business, with the formulations segment finally beginning to fire. With volume commitment for TLD from the Global Fund for the next 3.5 years, as well as ~US$ 12-15mn orders in hand from an EU partner and ongoing supplies of Metformin and HCQ to the US, we have high visibility on ~US$ 40mn formulations revenue in FY20E. This significant ramp up in formulations will drive oplev and margin expansion.


Outlook


Overall, we estimate 12/42/88% rev/EBITDA/earnings CAGR over FY19-21E. The stock is currently trading at attractive valuations of 22.6/13.5x FY20/21E EPS. We maintain BUY with a TP of Rs 535 (18x FY21E EPS). Refer our Jan-19 IC note for further details.


For all recommendations report, click here


Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.



Get Lok Sabha 2019 Live Election Results, constituency-wise tally, news, views and analysis
Follow our Lok Sabha Election Result Live Blog here.
First Published on Mar 28, 2019 03:23 pm
More From
Loading...
Sections
Follow us on
Available On
PCI DSS Compliant